The latest KFF Health Tracking Poll has revealed interesting insights into the public’s use and views of GLP-1 drugs. GLP-1 agonists, a class of prescription drugs gaining popularity for weight loss and treating diabetes or preventing heart attacks or strokes in adults with heart disease, have been reported to be taken by about one in eight adults. Among them, 6% are currently using these drugs. The prevalence of GLP-1 drug usage increases significantly among adults diagnosed with diabetes, heart disease, or those who are overweight or obese.
Public awareness of GLP-1 drugs has surged over the past year, with 32% of adults now indicating that they have heard ‘a lot’ about these medications, compared to 19% in the previous year. The majority of adults using GLP-1 drugs do so to manage chronic conditions like diabetes or heart disease, while a substantial proportion use them primarily for weight loss.
However, affordability remains a significant concern, with 54% of adults finding it challenging to cover the costs of GLP-1 drugs, including 22% who describe it as ‘very difficult.’ Despite most insured adults receiving some coverage for these drugs, approximately half of them still struggle to afford the expenses.
Among adults aged 65 and above, the usage of GLP-1 drugs for chronic conditions is higher at 8%, whereas only 1% have used these medications for weight loss. This discrepancy could be attributed to Medicare’s non-coverage of prescription drugs for weight loss. The findings shed light on the accessibility and financial barriers faced by individuals seeking to benefit from GLP-1 drugs.
